

Bob Champion Cancer Trust

Unaudited

Trustees' Report and Financial Statements

For the year ended 30 June 2023

Bob Champion Cancer Trust

Contents

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 8
Trustees' responsibilities statement	9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Notes to the financial statements	13 - 24

Bob Champion Cancer Trust

Reference and administrative details of the Charity, its Trustees and advisers For the year ended 30 June 2023

Founder

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)

President

Bob Champion, C.B.E.

Medical Advisor

Professor David Dearnaley

Vice Presidents

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Chris Hughes

Jonjo O'Neill

Greg Rusedski, Esq.

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

Trustees

Michael I Cattermole, Esq. (Chairman)

Susie Burrage, O.B.E.

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

Trust Officer

Mrs. Lucienne Wilkinson

Charity registered number

1024664

Principal Office

7 Square Rigger Row

Plantation Wharf

London

SW11 3TZ

Accountants

UHY Hacker Young

Chartered Accountants

Thames House

Roman Square

Sittingbourne

Kent ME10 4BJ

Bob Champion Cancer Trust

Trustees' report For the year ended 30 June 2023

The Trustees present their report and the accounts for the year ended 30 June 2023.

The financial statements comply with the charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) (Charities SORP (FRS 102)).

Structure, Governance and Management

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year in person or online.

Please see page 1 for Trustee details, legal and other administrative detail.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

Objectives and Activities

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate and testis.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust with The University of East Anglia (UEA) opened The Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2023

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donation with the benefit of claiming Gift Aid if applicable. Income is raised from a full fundraising calendar, with major events being held annually or biennially, supported by event committees, promotional mailings and active social media campaigns. The events range from themed event and parties, horse shows and race nights to personal challenges such as sponsored rides, marathons, including the London Marathon, and cycling events, these hopefully offer something for all our supporters and helps to attract new interest to the cause. A annual charity raceday at Plumpton Racecourse is held, which is now an established and extremely popular fundraiser for the Trust, during which a Shetland Pony race is held to help raise funds as well as the traditional auctions and raffles. Another very successful event is a carol service - Carols and Champagne - held at Chelsea Old Church in London every other year. The calendar had two extra events this year, to be held later in 2023, a charity golf day at Naunton Downs, near Cheltenham, and a further charity raceday, including a charity race, at Wincanton Racecourse.

The Trust is delighted to be continuing its involvement with the Shetland Pony Grand National, now for the seventh year. The Shetland Pony Grand National is a major part of the London International Horseshow held at Excel Exhibition Centre, with the Shetland Pony Grand National grand finale a highlight of the five days. Bob Champion himself is heavily involved during the year, helping the young riders through their heats, and attends, as well as appearing in the show ring every day during the Show in December. The jockeys (aged between 9-14 years) once they qualify for the Show commit to raise a minimum of £1,000 sponsorship in support of the Trust.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card. The card not only raises vital funds but spreads awareness of the cause and the work of the Trust. The artist/s is selected each year and kindly donate their time, or only charges for material costs, and skill in support of the Trust. In 2021 a second, smaller card, was added to create a choice for our supporters, again, double sided and kindly painted for us and donated by the artist. The larger card offers a more classic choice with the smaller card being more fun.

Bob Champion was awarded a CBE in The Queen's New Year Honours 2021 for his charitable works. He attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to offer help to cancer sufferers, their families and friends.

Public Benefit

The Trustees confirm that they given due consideration to the Charity Commission's published guidance on the Public Benefit requirement under the Charities Act 2011 when reviewing the aims and objectives, and in planning future activities.

Achievements and performance

Each year 52,000 men in the UK will be diagnosed with prostate cancer and more than 12,000 will die from their disease. At present we do not have good markers to predict who will have prostate cancer that behaves in an aggressive way and causes mortality.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2023

Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer.

A particular problem is the highly variable natural history of prostate cancer causes significant problems in its clinical management. Over-treatment of prostate cancers is a particular concern leading to impotence in a high proportion of cases. This is especially true for PSA screen-detected cancers that are mostly biologically irrelevant and in the absence of treatment would never become life threatening. Conversely, more conservative approaches to disease detection and management may leave potentially aggressive cancers untreated.

The Trust, within the Bob Champion Education and Research Building is continuing to fund a project aimed at identifying improved clinical markers (biomarkers) which allow radical therapies such as surgery and radiotherapy to be targeted to men with significant cancers, so that the remainder, with biologically unimportant disease, are spared the side-effects of treatment. Professor Cooper, Chair of Cancer Genetics at the University of East Anglia, is co-lead with Professor Ros Eeles (Institute of Cancer Research) on the global initiative PanProstate Cancer Group. The Pan Prostate Cancer Group (PPCG) consists of groups worldwide (UK, Germany, USA, Canada, France, Australia, Finland) that have whole genome, transcriptome and epigenome data from over 2000 prostate tumours linked to rich clinical outcome information. The consortium's data represent both localised and metastatic prostate cancers that also address differences in ethnicity, DNA repair gene carrier status, common germline variant polygenic risk status and variable age groups. Importantly, long-term outcome is also available on many of these patients and so clinic-genomic correlates can be made to determine novel factors that predict biochemical failure-free, and metastasis-free, survival. The major objective of the consortium is to identify markers that will allow us to distinguish between aggressive and non-aggressive prostate cancer at the time of diagnosis or metastasis. This represents a fundamental problem for around half of the 500,000 men diagnosed with prostate cancer in Europe and North America each year. Additionally, the data should provide insights into disease mechanism and identify possible new treatment paradigms.

Professor Cooper remains involved in Strategic Developments at UEA including facilitating translational research between the University and the Norwich Hospital where 5,000 patients are diagnosed with cancer each year including 750 patients with prostate cancer and 10-20 with testicular cancer. These themes form the basis of three projects currently funded by the Trust at UEA/Bob Champion Research and Education Building.

There have been two exciting results from the PUR2 studies. The first is that based on the work that Professor Cooper's team has done the hope to move immediately to accreditation which means patients can receive the test and the feedback will assist the progress of the project. The test can be used to detect expression of 20,000 genes in urine for immediate accreditation as it's the same technique that team used for the Tiger Test. The second is that the genes that are being detected may be reflecting the biology of the prostate as a whole rather than only the cancer. This fits in with a lot of the existing literature but represents a completely new way of detecting aggressive disease. Looking at the prostate as a whole (cancer plus surrounding tissue) rather than just focusing just on the cancer.

This is the first year of the Trust support for Professor Ros Eeles three year grant for the UKGPCS collection of germline DNA and data. The aim of this project is to analyse whole exome sequence from a unique and large collection of prostate cancer cases: 20,000 germline DNA samples from the UKGPCS in order to identify rare variants and their contribution to the risk of developing prostate cancer with specific phenotypes and potentially predict response to various treatments.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2023

The UKGPCS was established in 1992, recruiting men from The Royal Marsden NHS Foundation Trust and Collaborative Centres (NHS Trust hospitals) throughout the UK and Northern Ireland, over 180 of which are from the National Cancer Research Network (NCRN).

The UKGPCS have collected a rich phenotype dataset for most of these samples: date of birth, diagnosis, and death if applicable; mode of detection; TNM Stage; Gleason score; primary treatment; vital status; geographic region based on referring hospital, or treatment hospital if information on the referring hospital was not available; self-reported BMI; self-reported ethnicity; and PSA at diagnosis for all patients, as well as for relatives, if available. The information on risk factors for prostate cancer, demographic characteristics, and clinical data are also collected routinely as part of medical care and clinical follow-up. Over 78% of the cohort has clinical data on treatment and outcomes are being followed up at 2, 5 and 10 years post diagnosis; this collection is still in process.

For sequencing of whole exomes in germline samples a high-throughput automated approach will be used to prepare high-quality genomic DNA for exome capture. The exome will be captured and sequenced on the latest technology in use at the Regeneron Genetics Centre.

Publications:-

Caution regarding the specificities of pan-cancer microbial structure.

Gihawi A, Cooper CS, Brewer DS. Microb Genom. 2023 Aug;9(8):mgen001088. doi: 10.1099/mgen.0.001088. PMID: 37555750

Major data analysis errors invalidate cancer microbiome findings.

Gihawi A, Ge Y, Lu J, Puiu D, Xu A, Cooper CS, Brewer DS, Perteau M, Salzberg SL. mBio. 2023 Oct 31;14(5):e0160723. doi: 10.1128/mbio.01607-23. Epub 2023 Oct 9. PMID: 37811944

[Comment: this is a critical already highly cited paper that shows that major work published in the top Journal Nature is incorrect.]

Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer.

Yazbek Hanna M, Winterbone M, O'Connell SP, Olivani M, Hurst R, Mills R, Cooper CS, Brewer DS, Clark J. Cancers (Basel). 2023 Jan 27;15(3):789. doi: 10.3390/cancers15030789. PMID: 36765747

Genomic evolution shapes prostate cancer disease type.

Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, Gundem G, Xu Y, Butler A, Anokian E, Pope BJ, Jung CH, Tarabichi M, Dentro SC, Farmery JHR; CRUK ICGC Prostate Group; Van Loo P, Warren AY, Gnanapragasam V, Hamdy FC, Bova GS, Foster CS, Neal DE, Lu YJ, Kote-Jarai Z, Fraser M, Bristow RG, Boutros PC, Costello AJ, Corcoran NM, Hovens CM, Massie CE, Lynch AG, Brewer DS, Eeles RA, Cooper CS, Wedge DC. Cell Genom. 2024 Mar 13;4(3):100511. doi: 10.1016/j.xgen.2024.100511. Epub 2024 Feb 29. PMID: 38428419

[Comment: UEA holds a joint patent with Oxford and Manchester to develop this work.]

Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis.

Wardale L, Cardenas R, Gnanapragasam VJ, Cooper CS, Clark J, Brewer DS. Curr Oncol. 2022 Dec 22;30(1):157-170. doi: 10.3390/curroncol30010013. PMID: 36661662 Free

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2023

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.

Buhigas C, Warren AY, Leung WK, Whitaker HC, Luxton HJ, Hawkins S, Kay J, Butler A, Xu Y, Woodcock DJ, Merson S, Frame FM, Sahli A, Abascal F; CRUK-ICGC Prostate Cancer Group; Martincorena I, Bova GS, Foster CS, Campbell P, Maitland NJ, Neal DE, Massie CE, Lynch AG, Eeles RA, **Cooper CS**, Wedge DC, Brewer DS. Mol Cancer. 2022 Sep 22;21(1):183. doi: 10.1186/s12943-022-01644-3. PMID: 36131292

The Trust is in the second year of a three year grant for Annie Gao, a Senior Radiotherapy Clinical Trials Co-ordinator at the Bob Champion Unit, Royal Marsden Hospital, Sutton.

The Unit has supported and lead the PACE trials which looks to use stereotactic body radiotherapy to deliver to the patient the prostate cancer treatment in 5 visits over 1-2 weeks. This pioneering treatment can target the cancer with pinpoint accuracy. This means a reduction in healthy tissue damage and enables men to complete and recover from treatment much faster than ever before. Initial results from the PACE-B trial have been published, showing that there were low rates of side effects after 2 years and suggesting that curative treatment can be given over a much-shortened period. This has positive implications for the patients experience of cancer treatment and subsequent quality of life.

Critical to the success of all these studies is the long-term follow-up of men after their initial radiotherapy treatment. Confidence that a patient is truly cured takes 10 years in men with localised prostate cancer as side effects can continue to develop over many years, a full estimation of the risks and benefits of a new treatment requires years of careful data collection.

Annie Gao focusses particularly on the long-term follow-up of patients. This enables the ICR to continue to monitor men for signs of cancer recurrence and side effects for long enough to be sure that the innovative radiotherapy treatment being tested is advantageous. The Unit continues to publish results in the highest calibre journals and publications.

Key trials in long term follow-up:

- The **IMRT (Intensity-Modulated Radiotherapy) trial** (495 patients) looked at targeting the prostate cancer more accurately, which in turn allowed for a larger dose of radiotherapy to be given. There were 5 groups of patients, each receiving slightly different doses of radiotherapy. The continued review of this comprehensive dataset enables us to learn more about which patients are likely to be cured with standard treatments and which require further escalation of therapy. Blood and biopsy translational work from this trial also sheds new light on the evolutionary genetics of prostate cancer.
- The **CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2023

- The **DELINEATE trial** (316 patients), looks at new ways of planning and giving radiotherapy for localised prostate cancer. New types of scanning techniques have allowed us to differentiate between the cancer and normal prostate tissue with greater certainty. The aim is to target the cancerous area with increased accuracy and a higher dose without risking damage to the normal prostate tissue. The Trust has directly impacted this trial by allowing it to extend the patient follow-up period from 5 to 10 years. This data collection is critical as the cure rates have so far been unprecedented with up to 96.7 % of patients being free of any prostate cancer at the 5-year follow-up timepoint. Further follow-up of these patients is necessary to ensure these excellent results are maintained at 10 years.
- The **PACE-C trial** compares stereotactic body radiotherapy (5 visits – SBRT uses precise daily image guidance to give remarkably accurate radiotherapy) with the now conventional IMRT (20 visits – see IMRT trials above). Since the application last year, recruitment to this trial has exceeded expectations and the trial closed early having already met its target of 1182 patients. These men are now in long-term follow-up, assessing side effects, patient quality of life and long-term cancer control.

Financial Review

The Trust incurred an overall deficit for the year of £44,860 (2022: £101,310). Included within the income and expenditure of the Trust for the year is a surplus on fundraising events of £105,137 (2022: £184,284) and dividends received of £46,366 (2022: £46,535). In addition, the unrealised gain on investments for the year to 30 June 2023 was £54,724 (2022: loss on investments of £87,321).

The Trustees are satisfied that the Trust's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the Trust to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

Plans for the Future

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at The Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

Bob Champion Cancer Trust

Trustees' report (continued)
For the year ended 30 June 2023

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

Approval

This report was approved by the Trustees and signed on its behalf by:

DocuSigned by:
Michael Cattermole
D17B32C730044CE...

Michael Cattermole
Trustee

DocuSigned by:
Luke Ponsonby
079868F1D2FD4CA...

Luke Ponsonby
Trustee

Date: 19 April 2024

Bob Champion Cancer Trust

**Statement of Trustees' responsibilities
For the year ended 30 June 2023**

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

DocuSigned by:
Michael Cattermole
D17B32C730044CE...

Michael Cattermole
Trustee
Date: 19 April 2024

DocuSigned by:
Luke Ponsonby
079866F1D2FD4CA...

Luke Ponsonby
Trustee

Bob Champion Cancer Trust

**Independent Examiner's Report
For the year ended 30 June 2023**

Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2023.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: 

Dated: 22 April 2024

Tracey Moore BFP ACA

UHY Hacker Young

Chartered Accountants

Bob Champion Cancer Trust

Statement of financial activities
For the year ended 30 June 2023

	Note	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:				
Donations and legacies	4	6,295	6,295	12,001
Other trading activities - Fundraising	5	177,711	177,711	279,015
Investments	6	46,366	46,366	46,535
Total income		<u>230,372</u>	<u>230,372</u>	<u>337,551</u>
Expenditure on:				
Raising funds		72,574	72,574	94,169
Charitable activities		257,382	257,382	257,371
Total expenditure		<u>329,956</u>	<u>329,956</u>	<u>351,540</u>
Net expenditure before net gains/(losses) on investments		(99,584)	(99,584)	(13,989)
Net gains/(losses) on investments		54,724	54,724	(87,321)
Net movement in funds		<u>(44,860)</u>	<u>(44,860)</u>	<u>(101,310)</u>
Reconciliation of funds:				
Total funds brought forward		1,573,711	1,573,711	1,675,021
Net movement in funds		(44,860)	(44,860)	(101,310)
Total funds carried forward		<u>1,528,851</u>	<u>1,528,851</u>	<u>1,573,711</u>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 13 to 24 form part of these financial statements.

Bob Champion Cancer Trust

Balance sheet
As at 30 June 2023


	Note	2023 £	2022 £
Fixed assets			
Tangible assets	12	1,119	1,839
Investments	13	1,506,195	1,576,471
		<u>1,507,314</u>	<u>1,578,310</u>
Current assets			
Debtors	14	4,282	274
Cash at bank and in hand		90,538	60,553
		<u>94,820</u>	<u>60,827</u>
Creditors: amounts falling due within one year	15	(73,283)	(65,426)
Net current assets / liabilities		<u>21,537</u>	<u>(4,599)</u>
Total net assets		<u><u>1,528,851</u></u>	<u><u>1,573,711</u></u>
Charity funds			
Unrestricted funds	17	1,528,851	1,573,711
Total funds		<u><u>1,528,851</u></u>	<u><u>1,573,711</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

 D17B32C730044CE ..

Michael Cattermole
Trustee

DocuSigned by:

 079866F1D2FD4CA ..

Luke Ponsonby
Trustee

Date: 19 April 2024

The notes on pages 13 to 24 form part of these financial statements.

Bob Champion Cancer Trust

Notes to the financial statements For the year ended 30 June 2023

1. General information

Bob Champion Cancer Trust is a registered charity in England and Wales registered under the charity number 1024664. The registered office is 7 Square Rigger Row, Plantation Wharf, London, SW11 3TZ.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

2.2 Basis of non-consolidation

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

2.3 Going concern

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts. The accounts have therefore been prepared on the going concern basis.

Bob Champion Cancer Trust

Notes to the financial statements For the year ended 30 June 2023

2. Accounting policies (continued)

2.4 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised and refer to the Trustees' report for more information about their contribution.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include management carried out by the Executive Officer. The Trust office is based on an office share which is donated to the Trust by the building owner.. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2023**

2. Accounting policies (continued)

2.6 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.7 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Computer equipment	-	25% reducing balance
--------------------	---	----------------------

2.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

2.9 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.10 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.11 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2023**

2. Accounting policies (continued)
2.12 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.13 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

2.14 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

4. Income from donations and legacies

	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Legacies	1,393	1,393	4,952
Other	4,902	4,902	7,049
Total 2023	<u>6,295</u>	<u>6,295</u>	<u>12,001</u>

In both the current and prior year all income from donations and legacies was in relation to unrestricted funds.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2023

5. Income from other trading activities - fundraising
Income from fundraising events

	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
General Fundraising	23,787	23,787	34,162
Christmas Season	12,670	12,670	26,769
Carols and Champagne	-	-	89,669
Shetland Pony Grand National	30,012	30,012	30,483
40for40	-	-	14,903
Plumpton Raceday	111,242	111,242	83,029
Total 2023	177,711	177,711	279,015

In both the current and prior year all income from fundraising was in relation to unrestricted funds.

6. Investment income

	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Listed securities	46,293	46,293	46,531
Bank deposits	73	73	4
Total 2023	46,366	46,366	46,535

In both the current and prior year all income from investments was in relation to unrestricted funds.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2023

7. Research Grants

	Grants to Institutions 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	72,574	72,574	94,169
Professor Colin Cooper grant - UEA	31,317	31,317	46,537
Clinician Annie Gao	31,543	31,543	31,543
Total 2023	<u>135,434</u>	<u>135,434</u>	<u>172,249</u>

Professor Ros Eeles, Prostate Cancer Sequencing Project at the ICR, commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19, this grant was put on hold in 2020 as the ICR focused efforts on research of the virus. However, the grant resumed in 2021.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded in January 2020 for two years at a cost of £80,000. Professor Cooper is Professor of Cancer Genetics and Associate Dean of Research at UEA. This grant was due to end in December 2021 and, in November 2021, this grant was extended. The BCCT will continue to fund the project with Rachel Hurst with funds being taken up to, but no later, than 31st December 2024. It has been agreed that BCCT will pay 75% of the total grant, approximately £50,000 per annum.

In June 2021, a grant extension was offered to support Dan Brewer within Professor Colin Cooper's team on the DESNT project. The grant covers the project for one year at £30,000, with a deadline of completion of December 2023.

Furthermore, in July 2021 a grant was offered to Annie Gao within the Bob Champion Unit, Royal Marsden Hospital. The agreed funding for £42,000 per year is for 3 years (including standard on-costs) commencing from 1st September 2021.

The Trustees are satisfied that the charity will have sufficient resources to fulfil future research grant commitments. The charity has a strong balance sheet position, which includes listed investments of £1,506,193 that can be turned into cash as required.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2023

8. Support and governance costs

	Grant funding of activities 2023 £	Support costs 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Premises costs	-	7,217	7,217	<i>10,046</i>
Other costs	-	21,298	21,298	<i>7,407</i>
Personnel costs	-	59,337	59,337	<i>53,787</i>
Governance costs	-	13,063	13,063	<i>13,320</i>
Professor Rosalind Eeles grant - Institute of Cancer Research	72,574	-	72,574	<i>94,169</i>
Professor Colin Cooper grant - UEA	31,317	-	31,317	<i>46,537</i>
Clinician Annie Gao	31,543	-	31,543	<i>31,543</i>
	<u>135,434</u>	<u>100,915</u>	<u>236,349</u>	<u><i>256,809</i></u>
<i>Total 2022</i>	<u><i>172,249</i></u>	<u><i>84,560</i></u>	<u><i>256,809</i></u>	

Governance costs comprise of bookkeeping fees, legal fees and independent examiner's fees.

9. Independent examiner's remuneration

	2023 £	<i>2022 £</i>
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	<u>5,940</u>	<u><i>9,120</i></u>

10. Staff costs

	2023 £	<i>2022 £</i>
Wages and salaries	56,000	<i>50,520</i>
Social security costs	1,657	<i>1,751</i>
Contribution to defined contribution pension schemes	1,680	<i>1,516</i>
	<u>59,337</u>	<u><i>53,787</i></u>

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2023

10. Staff costs (continued)

The average number of persons employed by the Charity during the year was as follows:

	2023	<i>2022</i>
	No.	<i>No.</i>
Employees	<u>1</u>	<u>1</u>

No employee received remuneration amounting to more than £60,000 in either year.

The total employment benefits of key management personnel were £59,337 (*2022: £53,787*).

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (*2022 - £NIL*).

During the year ended 30 June 2023, no Trustee expenses have been incurred (*2022 - £NIL*).

12. Tangible fixed assets

	Office equipment £
Cost	
At 1 July 2022	6,782
At 30 June 2023	<u>6,782</u>
Depreciation	
At 1 July 2022	4,943
Charge for the year	720
At 30 June 2023	<u>5,663</u>
Net book value	
At 30 June 2023	<u>1,119</u>
<i>At 30 June 2022</i>	<u>1,839</u>

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2023**

13. Fixed asset investments

	Investments in subsidiary companies £	Listed investments £	Total £
Cost or valuation			
At 1 July 2022	2	1,576,469	1,576,471
Disposals	-	(125,000)	(125,000)
Revaluations	-	54,724	54,724
At 30 June 2023	<u>2</u>	<u>1,506,193</u>	<u>1,506,195</u>

At 30 June 2023, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,506,193 (2022: £1,576,469). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain/(loss) is included in the statement of financial activities.

Subsidiary undertakings

The following was a subsidiary undertaking of the Charity:

Name	Holding	Included in consolidation
Aldaniti Trading Company Limited	100%	Yes

The financial results of the subsidiary for the year were:

Name	Net assets £
Aldaniti Trading Company Limited	2

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

14. Debtors

	2023 £	2022 £
Due within one year		
Prepayments	<u>4,282</u>	<u>274</u>

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2023

15. Creditors: Amounts falling due within one year

	2023	<i>2022</i>
	£	£
Trade creditors	34,973	1,100
Amounts owed to group undertakings	2	2
Other taxation and social security	1,199	1,091
Other creditors	265	249
Accruals and deferred income	29,295	15,966
Grants committed	7,549	47,018
	<u>73,283</u>	<u>65,426</u>
	2023	<i>2022</i>
	£	£
Events income deferred during the year	<u>12,975</u>	<u>-</u>

16. Financial instruments

	2023	<i>2022</i>
	£	£
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>1,506,193</u>	<u>1,576,469</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2023

17. Statement of funds**Statement of funds - current year**

	As restated Balance at 1 July 2022	Income	Expenditure	Gains/ (Losses)	Balance at 30 June 2023
	£	£	£	£	£
Unrestricted funds					
Reserves	1,573,711	230,372	(329,956)	54,724	1,528,851
	<u>1,573,711</u>	<u>230,372</u>	<u>(329,956)</u>	<u>54,724</u>	<u>1,528,851</u>

Statement of funds - prior year

	<i>Balance at 1 July 2021</i>	<i>Income</i>	<i>As restated Expenditure</i>	<i>Gains/ (Losses)</i>	<i>As restated Balance at 30 June 2022</i>
	£	£	£	£	£
Unrestricted funds					
Reserves	1,675,021	337,551	(351,540)	(87,321)	1,573,711
	<u>1,675,021</u>	<u>337,551</u>	<u>(351,540)</u>	<u>(87,321)</u>	<u>1,573,711</u>

18. Analysis of net assets between funds**Analysis of net assets between funds - current year**

	Unrestricted funds 2023	Total funds 2023
	£	£
Tangible fixed assets	1,119	1,119
Fixed asset investments	1,506,195	1,506,195
Current assets	94,820	94,820
Creditors due within one year	(73,283)	(73,283)
Total	<u>1,528,851</u>	<u>1,528,851</u>

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2023

18. Analysis of net assets between funds (continued)**Analysis of net assets between funds - prior year**

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Tangible fixed assets	1,839	1,839
Fixed asset investments	1,576,471	1,576,471
Current assets	60,827	60,827
Creditors due within one year	(65,426)	(65,426)
Total	<u>1,573,711</u>	<u>1,573,711</u>

19. Pension commitments

The group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the group in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,680 (2022: £1,516). Contributions totaling £265 (2022: £233) were payable to the fund at the balance sheet date and are included in creditors.

20. Related party transactions

During the year, the charity paid £29,879 (2022: £27,612) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £7,479 (2022: £6,200). Bob Champion's retainer has been approved by the Charity Commission.